Ulefnersen Trial Met Primary Endpoints
The experimental drug improved function and survival in patients with FUS-ALS during a late-stage clinical study.
Updated on Sept. 22, 2026 in Alzheimer’s
Live Poll
Should pharmaceutical companies accelerate the development of experimental drugs for rare, fatal conditions?
Otsuka Pharmaceutical and Ionis Pharmaceuticals announced that their experimental drug, ulefnersen, met its primary endpoint in a late-stage trial for FUS-ALS. The therapy demonstrated improvements in patient function and survival compared to a placebo.
Why it matters
FUS-ALS is a severe condition that causes progressive muscle weakness and nerve cell damage, yet no existing treatments target its specific genetic cause. This drug potentially fills a critical gap by addressing the root production of the FUS protein.
In a late-stage study, ulefnersen improved patient function and survival versus a placebo control group while reducing markers linked to nerve cell damage. Researchers are still evaluating the long-term impact on disease progression across different patient demographics.
The players
Otsuka Pharmaceutical
This is a global healthcare company that researches and develops pharmaceutical products for various diseases.
Ionis Pharmaceuticals
This company specializes in RNA-targeted therapies to treat diseases with high unmet medical needs.
The details
Ulefnersen works by reducing the production of the harmful FUS protein, which is the underlying cause of the disease. Most reported side effects in the study were categorized as mild or moderate.
Timeline
September 22, 2026: Companies reported positive results from the late-stage trial.
The Big Picture
The development of ulefnersen represents a targeted effort to utilize the FDA accelerated approval pathway to address rare genetic conditions. This approach follows a pattern of recent biotech breakthroughs that prioritize therapies for diseases lacking any existing treatment options.
Eligible patients may now request access to the drug through a newly launched global early access program facilitated by physicians. This program offers a potential pathway to treatment while the companies seek formal regulatory approvals worldwide.
The takeaway
Patients or caregivers should consult with their healthcare providers regarding the eligibility criteria for the new early access program. This development marks a significant step forward in targeting the underlying genetic drivers of FUS-ALS.
Further reading
Learn more about the latest research and developments in neurodegenerative medicine at the Alzheimer’s section.
Live Poll
Should pharmaceutical companies accelerate the development of experimental drugs for rare, fatal conditions?
